Nuwellis Announces Presentation of Aquadex®-Related Abstracts at the 2022 Pediatric Academic Societies Meeting
“We are excited to add to the ever-growing body of research supporting the negative impact of fluid excess and the benefits of Aquadex,” said
Aquadex SmartFlow® ultrafiltration enables gentle, precise, and adjustable fluid removal, helping achieve the desired fluid balance with only 35 mL (around 2.5 tablespoons) of blood outside of the body. The customizable rate of fluid removal is particularly important for pediatric patients, who have a small amount of blood in their bodies. Aquadex is cleared by the FDA for use in adults and pediatric patients weighing 20 kg (44 lbs.) or more.
“Ultrafiltration using the Aquadex system provides an easy to use, safe and effective therapy for managing fluid balance in pediatric patients,” said
About the Aquadex SmartFlow System
The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible, and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.
Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the new market opportunities and anticipated growth in 2022 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our ability to execute on our commercialization strategy, the impact of the COVID-19 pandemic, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the
George Montague, CFA Chief Financial Officer, Nuwellis, Inc.email@example.com Matt Bacso, CFA Gilmartin Group LLCMatt.Bacso@gilmartinir.com MEDIA: Sarah LundbergHealth+Commerce firstname.lastname@example.org
Source: Nuwellis, Inc.